Pyxis Oncology, a Boston-based biotech company, has raised $152 million in a Series B financing round co-led by Arix Bioscience and RTW Investments. The company is developing antibody-drug conjugates (ADCs), immunotherapies, and other biologics for the treatment of difficult-to-treat cancers. Pyxis Oncology’s Series B round also saw the participation of additional new investors – Perceptive […]
Pfizer said that it has initiated a phase 1 study in the US for assessing the oral antiviral therapeutic PF-07321332 against SARS-CoV-2, the virus that causes Covid-19. The US pharma giant said that it has completed the dosing of single ascending doses in the participating healthy adults in the early-stage clinical trial. Pfizer will now […]
US pharmaceutical giant Pfizer has withdrawn its application for emergency use authorization of its BNT162b2 COVID-19 vaccine in India. This decision comes after a series of interactions with the Indian drug regulator, which had requested additional information regarding the vaccine. Regulatory Hurdles and Safety Concerns Initially submitted for approval in December 2020, the application faced […]
Cabenuva FDA approval : ViiV Healthcare has secured approval from the US Food and Drug Administration (FDA) for its long-acting regimen Cabenuva for the treatment of HIV-1 infection in adult patients. According to ViiV Healthcare, Cabenuva is being given as a co-pack with a couple of injectable medicines that include the company’s integrase strand transfer […]
Swissmedic, the Swiss Agency for Therapeutic Products, has authorized the use of the BNT162b2 Covid-19 vaccine from US pharma giant Pfizer and German biotech company BioNTech. The Swiss pharma regulator said that as per the data it has assessed, the level of protection afforded seven days following the second dose of the mRNA vaccine is […]
BNT162b2 FDA EUA : Pfizer and BioNTech have been granted emergency use authorization (EUA) from the US Food and Drug Administration (FDA) for BNT162b2, their Covid-19 mRNA vaccine. BNT162b2 has been authorized by the FDA for its use in the prevention of Covid-19 in individuals aged 16 years or more. Pfizer and BioNTech will look […]
US pharma giant Pfizer and German biotech company BioNTech have bagged Health Canada approval for their BNT162b2 Covid-19 vaccine. The BNT162b2 vaccine has been authorized to be used in Canada under the regulator’s Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to Covid-19. Canada has now joined the UK […]
PostEra, a biotech company specializing in machine learning solutions for preclinical drug discovery, has forged a partnership with Pfizer for speeding up the discovery of small molecule drugs by using a platform technology based on generative chemistry. The company’s machine learning technology can fast track the drug discovery process by designing novel molecular structures that […]
The UK has given a temporary authorization for emergency use for the BNT162b2 Covid-19 vaccine candidate developed by Pfizer and BioNTech. The emergency use authorization (EUA) from the UK Medicines & Healthcare Products Regulatory Agency (MHRA) for the mRNA vaccine candidate follows the release of positive results of a global phase 3 trial. Pfizer and […]
Olema Oncology has entered into a clinical trial agreement with Pfizer to evaluate its small molecule OP-1250 in combination with the latter’s palbociclib (IBRANCE) in advanced breast cancer. OP-1250 is an estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). Its combination with the Pfizer breast cancer drug will be assessed in the […]